La Monica S et al. |
Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines. |
2017 |
J. Exp. Clin. Cancer Res. |
pmid:29202823
|
Sun X et al. |
Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. |
2017 |
Bioconjug. Chem. |
pmid:28388844
|
Eckelmann D et al. |
Spatial profiling of maytansine during the germination process of Maytenus senegalensis seeds. |
2017 |
Fitoterapia |
pmid:28385670
|
Thuss-Patience PC et al. |
Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. |
2017 |
Lancet Oncol. |
pmid:28343975
|
Beck A et al. |
Strategies and challenges for the next generation of antibody-drug conjugates. |
2017 |
Nat Rev Drug Discov |
pmid:28303026
|
Chuang JC et al. |
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. |
2017 |
J Thorac Oncol |
pmid:28167203
|
Liu Y et al. |
LC-MS/MS method for the simultaneous determination of Lys-MCC-DM1, MCC-DM1 and DM1 as potential intracellular catabolites of the antibody-drug conjugate trastuzumab emtansine (T-DM1). |
2017 |
J Pharm Biomed Anal |
pmid:28131055
|
Daniels B et al. |
Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort. |
2017 |
BMJ Open |
pmid:28119394
|
Kosmin M et al. |
Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer. |
2017 |
Target Oncol |
pmid:28110417
|
Andreev J et al. |
Bispecific Antibodies and Antibody-Drug Conjugates (ADCs) Bridging HER2 and Prolactin Receptor Improve Efficacy of HER2 ADCs. |
2017 |
Mol. Cancer Ther. |
pmid:28108597
|
Stefan N et al. |
Highly Potent, Anthracycline-based Antibody-Drug Conjugates Generated by Enzymatic, Site-specific Conjugation. |
2017 |
Mol. Cancer Ther. |
pmid:28258164
|
Wang H et al. |
Albumin nanoparticle encapsulation of potent cytotoxic therapeutics shows sustained drug release and alleviates cancer drug toxicity. |
2017 |
Chem. Commun. (Camb.) |
pmid:28195282
|
Zhong P et al. |
αβ Integrin-targeted reduction-sensitive micellar mertansine prodrug: Superb drug loading, enhanced stability, and effective inhibition of melanoma growth in vivo. |
2017 |
J Control Release |
pmid:27986551
|
Wang LL et al. |
A Bio-Chemosynthetic Approach to Superparamagnetic Iron Oxide-Ansamitocin Conjugates for Use in Magnetic Drug Targeting. |
2017 |
Chemistry |
pmid:27935144
|
Mercogliano MF et al. |
TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer. |
2017 |
Clin. Cancer Res. |
pmid:27698002
|
Lin J and Zhong JJ |
Proteomic studies on anti-tumor agent ansamitocin P-3 producer Actinosynnema pretiosum in response to ammonium and isobutanol. |
2017 |
Bioprocess Biosyst Eng |
pmid:28382459
|
Martin LP et al. |
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRα-targeting antibody-drug conjugate mirvetuximab soravtansine. |
2017 |
Gynecol. Oncol. |
pmid:28843653
|
Wang H et al. |
Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. |
2017 |
Cancer Sci. |
pmid:28388007
|
Lambert JM and Morris CQ |
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. |
2017 |
Adv Ther |
pmid:28361465
|
Socinski MA et al. |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease. |
2017 |
Clin Lung Cancer |
pmid:28341109
|